Join the club for FREE to access the whole archive and other member benefits.

Funding to build biological nanorobots


Key points from article :

Founded in 2014, France-based Eligo Bioscience has received $20m Series A funding.

Aims is to treat a number of diseases using the human microbiome.

Eligo’s biological nanobots (aka eligobots) are made from DNA and protein.

Able to deliver a customised therapeutic payload to specific types of bacteria.

Nanobots can either kill the bacteria or transiently turn them into drug producers.

Mentioned in this article:

Click on resource name for more details.

Eligo Bioscience

Synthetic Biology company for targeted antimicrobials and microbiome editing.

Xavier Duportet

CEO at Eligo Bioscience.

Topics mentioned on this page: